Jump to section
IdentificationPharmacologyInteractionsReferencesTrialsEconomicsPropertiesSpectraTaxonomyBucindolol
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Name
- Bucindolol
- Accession Number
- DB12752
- Type
- Small Molecule
- Groups
- Investigational
- Description
Bucindolol has been investigated in Heart Failure.
- Structure
Structure for DB12752 (Bucindolol)
- Synonyms
- Not Available
- Categories
- Adrenergic Agents
- Adrenergic alpha-1 Receptor Antagonists
- Adrenergic alpha-Antagonists
- Adrenergic Antagonists
- Adrenergic beta-Antagonists
- Alcohols
- Amines
- Amino Alcohols
- Autonomic Agents
- Cardiovascular Agents
- Neurotransmitter Agents
- Peripheral Nervous System Agents
- Propanols
- Sympathomimetics
- Vasodilator Agents
- UNII
- E9UO06K7CE
- CAS number
- 71119-11-4
- Weight
- Average: 363.461
Monoisotopic: 363.194677057 - Chemical Formula
- C22H25N3O2
- InChI Key
- FBMYKMYQHCBIGU-UHFFFAOYSA-N
- InChI
- InChI=1S/C22H25N3O2/c1-22(2,11-17-13-24-20-9-5-4-8-19(17)20)25-14-18(26)15-27-21-10-6-3-7-16(21)12-23/h3-10,13,18,24-26H,11,14-15H2,1-2H3
- IUPAC Name
- 2-(2-hydroxy-3-{[1-(1H-indol-3-yl)-2-methylpropan-2-yl]amino}propoxy)benzonitrile
- SMILES
- CC(C)(CC1=CNC2=CC=CC=C12)NCC(O)COC1=CC=CC=C1C#N
Pharmacology
- Indication
- Not Available
- Structured Indications
- Not Available
- Pharmacodynamics
- Not Available
- Mechanism of action
- Not Available
- Absorption
- Not Available
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
- Not Available
- Route of elimination
- Not Available
- Half life
- Not Available
- Clearance
- Not Available
- Toxicity
- Not Available
- Affected organisms
- Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
Drug Interaction Drug group (4R)-limonene (4R)-limonene may decrease the antihypertensive activities of Bucindolol. Investigational 1,10-Phenanthroline 1,10-Phenanthroline may increase the bradycardic activities of Bucindolol. Experimental 4-Methoxyamphetamine 4-Methoxyamphetamine may increase the atrioventricular blocking (AV block) activities of Bucindolol. Experimental, Illicit Acebutolol Acebutolol may increase the orthostatic hypotensive activities of Bucindolol. Approved, Investigational Aceclofenac Aceclofenac may decrease the antihypertensive activities of Bucindolol. Approved, Investigational Acemetacin Acemetacin may decrease the antihypertensive activities of Bucindolol. Approved, Experimental, Investigational Acepromazine Acepromazine may increase the hypotensive activities of Bucindolol. Approved, Vet Approved Aceprometazine Aceprometazine may increase the hypotensive activities of Bucindolol. Approved Acetohexamide Bucindolol may increase the hypoglycemic activities of Acetohexamide. Approved, Investigational, Withdrawn Acetylcholine The risk or severity of adverse effects can be increased when Bucindolol is combined with Acetylcholine. Approved Acetyldigitoxin Bucindolol may increase the bradycardic activities of Acetyldigitoxin. Approved Acetyldigoxin Bucindolol may increase the bradycardic activities of Acetyldigoxin. Experimental Acetylsalicylic acid Acetylsalicylic acid may decrease the antihypertensive activities of Bucindolol. Approved, Vet Approved Adapalene Adapalene may decrease the antihypertensive activities of Bucindolol. Approved Adrafinil Bucindolol may decrease the vasoconstricting activities of Adrafinil. Withdrawn Agmatine Agmatine may increase the atrioventricular blocking (AV block) activities of Bucindolol. Experimental, Investigational Alaproclate The serum concentration of Bucindolol can be increased when it is combined with Alaproclate. Experimental Alclofenac Alclofenac may decrease the antihypertensive activities of Bucindolol. Approved, Withdrawn Alfentanil Alfentanil may increase the bradycardic activities of Bucindolol. Approved, Illicit Alfuzosin Alfuzosin may increase the antihypertensive activities of Bucindolol. Approved, Investigational Alimemazine Alimemazine may increase the hypotensive activities of Bucindolol. Approved, Vet Approved Alminoprofen Alminoprofen may decrease the antihypertensive activities of Bucindolol. Experimental Alprenolol Alprenolol may increase the orthostatic hypotensive activities of Bucindolol. Approved, Withdrawn Ambenonium Ambenonium may increase the bradycardic activities of Bucindolol. Approved Amibegron Bucindolol may decrease the vasoconstricting activities of Amibegron. Investigational Amiodarone The therapeutic efficacy of Bucindolol can be increased when used in combination with Amiodarone. Approved, Investigational Amitraz Bucindolol may decrease the vasoconstricting activities of Amitraz. Vet Approved Amlodipine The risk or severity of hypotension can be increased when Bucindolol is combined with Amlodipine. Approved Amobarbital The serum concentration of Bucindolol can be decreased when it is combined with Amobarbital. Approved, Illicit Amodiaquine The metabolism of Bucindolol can be decreased when combined with Amodiaquine. Approved, Investigational Amphetamine The risk or severity of adverse effects can be increased when Amphetamine is combined with Bucindolol. Approved, Illicit, Investigational Amrinone The risk or severity of hypotension can be increased when Bucindolol is combined with Amrinone. Approved Andrographolide Andrographolide may decrease the antihypertensive activities of Bucindolol. Investigational Anisodamine Bucindolol may decrease the vasoconstricting activities of Anisodamine. Investigational Antipyrine Antipyrine may decrease the antihypertensive activities of Bucindolol. Approved, Investigational Apocynin Apocynin may decrease the antihypertensive activities of Bucindolol. Investigational Apomorphine Apomorphine may increase the atrioventricular blocking (AV block) activities of Bucindolol. Approved, Investigational Apraclonidine Bucindolol may decrease the vasoconstricting activities of Apraclonidine. Approved Apremilast Apremilast may decrease the antihypertensive activities of Bucindolol. Approved, Investigational Aranidipine The risk or severity of hypotension can be increased when Bucindolol is combined with Aranidipine. Approved, Investigational Arbutamine Bucindolol may decrease the vasoconstricting activities of Arbutamine. Approved Arecoline The risk or severity of adverse effects can be increased when Bucindolol is combined with Arecoline. Experimental Arformoterol Bucindolol may decrease the vasoconstricting activities of Arformoterol. Approved, Investigational Arotinolol Arotinolol may increase the orthostatic hypotensive activities of Bucindolol. Investigational Atenolol Atenolol may increase the orthostatic hypotensive activities of Bucindolol. Approved Atomoxetine Atomoxetine may increase the hypertensive activities of Bucindolol. Approved Avanafil Avanafil may increase the hypotensive activities of Bucindolol. Approved Azapropazone Azapropazone may decrease the antihypertensive activities of Bucindolol. Withdrawn Azelastine Azelastine may decrease the antihypertensive activities of Bucindolol. Approved Azelnidipine The risk or severity of hypotension can be increased when Bucindolol is combined with Azelnidipine. Approved, Investigational Azimilide The risk or severity of hypotension can be increased when Bucindolol is combined with Azimilide. Investigational Balsalazide Balsalazide may decrease the antihypertensive activities of Bucindolol. Approved, Investigational Barbexaclone The serum concentration of Bucindolol can be decreased when it is combined with Barbexaclone. Experimental Barbital The serum concentration of Bucindolol can be decreased when it is combined with Barbital. Illicit Barnidipine The risk or severity of hypotension can be increased when Bucindolol is combined with Barnidipine. Approved Befunolol Befunolol may increase the orthostatic hypotensive activities of Bucindolol. Experimental Bencyclane The risk or severity of hypotension can be increased when Bucindolol is combined with Bencyclane. Experimental Bendazac Bendazac may decrease the antihypertensive activities of Bucindolol. Experimental Benidipine The risk or severity of hypotension can be increased when Bucindolol is combined with Benidipine. Approved, Investigational Benorilate Benorilate may decrease the antihypertensive activities of Bucindolol. Experimental Benoxaprofen Benoxaprofen may decrease the antihypertensive activities of Bucindolol. Withdrawn Benzphetamine Benzphetamine may increase the atrioventricular blocking (AV block) activities of Bucindolol. Approved, Illicit Benzydamine Benzydamine may decrease the antihypertensive activities of Bucindolol. Approved Bepridil The risk or severity of hypotension can be increased when Bucindolol is combined with Bepridil. Approved, Withdrawn Betaxolol Betaxolol may increase the orthostatic hypotensive activities of Bucindolol. Approved, Investigational Bethanechol The risk or severity of adverse effects can be increased when Bucindolol is combined with Bethanechol. Approved Bethanidine Bethanidine may increase the atrioventricular blocking (AV block) activities of Bucindolol. Approved Bevantolol Bevantolol may increase the orthostatic hypotensive activities of Bucindolol. Approved Bevonium Bevonium may decrease the antihypertensive activities of Bucindolol. Experimental Bioallethrin The risk or severity of hypotension can be increased when Bucindolol is combined with Bioallethrin. Approved, Experimental Bisoprolol Bisoprolol may increase the orthostatic hypotensive activities of Bucindolol. Approved Bitolterol Bucindolol may decrease the vasoconstricting activities of Bitolterol. Withdrawn BL-1020 BL-1020 may increase the hypotensive activities of Bucindolol. Investigational Bopindolol Bopindolol may increase the orthostatic hypotensive activities of Bucindolol. Approved Brimonidine Brimonidine may increase the atrioventricular blocking (AV block) activities of Bucindolol. Approved Bromfenac Bromfenac may decrease the antihypertensive activities of Bucindolol. Approved Bromocriptine Bromocriptine may increase the atrioventricular blocking (AV block) activities of Bucindolol. Approved, Investigational Bucillamine Bucillamine may decrease the antihypertensive activities of Bucindolol. Investigational Bufexamac Bufexamac may decrease the antihypertensive activities of Bucindolol. Approved, Experimental Bufuralol Bufuralol may increase the orthostatic hypotensive activities of Bucindolol. Experimental, Investigational Bumadizone Bumadizone may decrease the antihypertensive activities of Bucindolol. Experimental Bunazosin Bunazosin may increase the antihypertensive activities of Bucindolol. Investigational Bupivacaine The serum concentration of Bupivacaine can be increased when it is combined with Bucindolol. Approved, Investigational Bupranolol Bupranolol may increase the orthostatic hypotensive activities of Bucindolol. Approved Cabergoline Bucindolol may increase the vasoconstricting activities of Cabergoline. Approved Carbachol The risk or severity of adverse effects can be increased when Bucindolol is combined with Carbachol. Approved Carbaspirin calcium Carbaspirin calcium may decrease the antihypertensive activities of Bucindolol. Experimental, Investigational Carboxyamidotriazole The risk or severity of hypotension can be increased when Bucindolol is combined with Carboxyamidotriazole. Investigational Carbutamide Bucindolol may increase the hypoglycemic activities of Carbutamide. Experimental Caroverine The risk or severity of hypotension can be increased when Bucindolol is combined with Caroverine. Experimental Carprofen Carprofen may decrease the antihypertensive activities of Bucindolol. Approved, Vet Approved, Withdrawn Carteolol Carteolol may increase the orthostatic hypotensive activities of Bucindolol. Approved Carvedilol Carvedilol may increase the antihypertensive activities of Bucindolol. Approved, Investigational Castanospermine Castanospermine may decrease the antihypertensive activities of Bucindolol. Experimental Celecoxib Celecoxib may decrease the antihypertensive activities of Bucindolol. Approved, Investigational Celiprolol Celiprolol may increase the orthostatic hypotensive activities of Bucindolol. Approved, Investigational Cevimeline The risk or severity of adverse effects can be increased when Bucindolol is combined with Cevimeline. Approved Chloroquine The metabolism of Bucindolol can be decreased when combined with Chloroquine. Approved, Investigational, Vet Approved Chlorphentermine The risk or severity of adverse effects can be increased when Chlorphentermine is combined with Bucindolol. Illicit, Withdrawn Chlorproethazine Chlorproethazine may increase the hypotensive activities of Bucindolol. Experimental Chlorpromazine Chlorpromazine may increase the hypotensive activities of Bucindolol. Approved, Investigational, Vet Approved Chlorpropamide Bucindolol may increase the hypoglycemic activities of Chlorpropamide. Approved, Investigational Choline magnesium trisalicylate Choline magnesium trisalicylate may decrease the antihypertensive activities of Bucindolol. Approved Cilnidipine The risk or severity of hypotension can be increased when Bucindolol is combined with Cilnidipine. Approved, Investigational Cinnarizine The risk or severity of hypotension can be increased when Bucindolol is combined with Cinnarizine. Approved, Investigational Cirazoline Bucindolol may decrease the vasoconstricting activities of Cirazoline. Experimental Clenbuterol The risk or severity of adverse effects can be increased when Clenbuterol is combined with Bucindolol. Approved, Investigational, Vet Approved Clevidipine The risk or severity of hypotension can be increased when Bucindolol is combined with Clevidipine. Approved, Investigational Clonidine Clonidine may increase the atrioventricular blocking (AV block) activities of Bucindolol. Approved Clonixin Clonixin may decrease the antihypertensive activities of Bucindolol. Approved Cloranolol Cloranolol may increase the orthostatic hypotensive activities of Bucindolol. Experimental Coumaphos Coumaphos may increase the bradycardic activities of Bucindolol. Vet Approved Curcumin Curcumin may decrease the antihypertensive activities of Bucindolol. Approved, Investigational Cyclandelate The risk or severity of hypotension can be increased when Bucindolol is combined with Cyclandelate. Approved Cymarin Bucindolol may increase the bradycardic activities of Cymarin. Experimental Dapoxetine Dapoxetine may increase the orthostatic hypotensive activities of Bucindolol. Investigational Darodipine The risk or severity of hypotension can be increased when Bucindolol is combined with Darodipine. Experimental Decamethonium Decamethonium may increase the bradycardic activities of Bucindolol. Approved Demecarium Demecarium may increase the bradycardic activities of Bucindolol. Approved Deslanoside Bucindolol may increase the bradycardic activities of Deslanoside. Approved Desvenlafaxine The serum concentration of Bucindolol can be increased when it is combined with Desvenlafaxine. Approved, Investigational Detomidine Bucindolol may decrease the vasoconstricting activities of Detomidine. Vet Approved Dexmedetomidine Dexmedetomidine may increase the atrioventricular blocking (AV block) activities of Bucindolol. Approved, Vet Approved Dichlorvos Dichlorvos may increase the bradycardic activities of Bucindolol. Vet Approved Diclofenac Diclofenac may decrease the antihypertensive activities of Bucindolol. Approved, Vet Approved Difenpiramide Difenpiramide may decrease the antihypertensive activities of Bucindolol. Experimental Diflunisal Diflunisal may decrease the antihypertensive activities of Bucindolol. Approved, Investigational Digitoxin Bucindolol may increase the bradycardic activities of Digitoxin. Approved, Investigational Digoxin Bucindolol may increase the bradycardic activities of Digoxin. Approved Digoxin Immune Fab (Ovine) Bucindolol may increase the bradycardic activities of Digoxin Immune Fab (Ovine). Approved Dihydroergotamine Dihydroergotamine may increase the atrioventricular blocking (AV block) activities of Bucindolol. Approved, Investigational Diltiazem Diltiazem may increase the hypotensive activities of Bucindolol. Approved, Investigational Dipivefrin Dipivefrin may increase the atrioventricular blocking (AV block) activities of Bucindolol. Approved Dipyridamole Dipyridamole may increase the bradycardic activities of Bucindolol. Approved Disopyramide Disopyramide may increase the bradycardic activities of Bucindolol. Approved Distigmine Distigmine may increase the bradycardic activities of Bucindolol. Experimental Dobutamine The risk or severity of adverse effects can be increased when Dobutamine is combined with Bucindolol. Approved Donepezil Donepezil may increase the bradycardic activities of Bucindolol. Approved Dopamine The risk or severity of adverse effects can be increased when Dopamine is combined with Bucindolol. Approved Dopexamine Bucindolol may decrease the vasoconstricting activities of Dopexamine. Approved, Investigational Dotarizine The risk or severity of hypotension can be increased when Bucindolol is combined with Dotarizine. Investigational Doxazosin Doxazosin may increase the antihypertensive activities of Bucindolol. Approved Doxofylline The risk or severity of adverse effects can be increased when Bucindolol is combined with Doxofylline. Approved, Investigational Dronabinol Dronabinol may increase the tachycardic activities of Bucindolol. Approved, Illicit Dronedarone Dronedarone may increase the bradycardic activities of Bucindolol. Approved Droxicam Droxicam may decrease the antihypertensive activities of Bucindolol. Withdrawn Droxidopa Droxidopa may increase the atrioventricular blocking (AV block) activities of Bucindolol. Approved, Investigational Duloxetine The serum concentration of Bucindolol can be increased when it is combined with Duloxetine. Approved Duvelisib Duvelisib may decrease the antihypertensive activities of Bucindolol. Investigational E-6201 E-6201 may decrease the antihypertensive activities of Bucindolol. Investigational Echothiophate Echothiophate may increase the bradycardic activities of Bucindolol. Approved Edrophonium Edrophonium may increase the bradycardic activities of Bucindolol. Approved Efonidipine The risk or severity of hypotension can be increased when Bucindolol is combined with Efonidipine. Approved, Investigational Epanolol Epanolol may increase the orthostatic hypotensive activities of Bucindolol. Experimental Eperisone The risk or severity of hypotension can be increased when Bucindolol is combined with Eperisone. Approved, Investigational Ephedra Ephedra may increase the atrioventricular blocking (AV block) activities of Bucindolol. Approved, Nutraceutical, Withdrawn Ephedrine The risk or severity of adverse effects can be increased when Ephedrine is combined with Bucindolol. Approved Epibatidine The risk or severity of adverse effects can be increased when Bucindolol is combined with Epibatidine. Experimental Epinastine Bucindolol may decrease the vasoconstricting activities of Epinastine. Approved, Investigational Epinephrine Epinephrine may increase the atrioventricular blocking (AV block) activities of Bucindolol. Approved, Vet Approved Epirizole Epirizole may decrease the antihypertensive activities of Bucindolol. Approved Ergoloid mesylate Bucindolol may increase the vasoconstricting activities of Ergoloid mesylate. Approved Ergonovine Bucindolol may increase the vasoconstricting activities of Ergonovine. Approved Ergotamine Ergotamine may increase the atrioventricular blocking (AV block) activities of Bucindolol. Approved Esmolol Esmolol may increase the orthostatic hypotensive activities of Bucindolol. Approved Etanercept Etanercept may decrease the antihypertensive activities of Bucindolol. Approved, Investigational Ethenzamide Ethenzamide may decrease the antihypertensive activities of Bucindolol. Experimental Ethosuximide The risk or severity of hypotension can be increased when Bucindolol is combined with Ethosuximide. Approved Etilefrine The risk or severity of adverse effects can be increased when Etilefrine is combined with Bucindolol. Withdrawn Etodolac Etodolac may decrease the antihypertensive activities of Bucindolol. Approved, Investigational, Vet Approved Etofenamate Etofenamate may decrease the antihypertensive activities of Bucindolol. Approved, Investigational Etomidate Etomidate may increase the atrioventricular blocking (AV block) activities of Bucindolol. Approved Etoperidone The serum concentration of Bucindolol can be increased when it is combined with Etoperidone. Withdrawn Etoricoxib Etoricoxib may decrease the antihypertensive activities of Bucindolol. Approved, Investigational Evening primrose oil Evening primrose oil may decrease the antihypertensive activities of Bucindolol. Investigational, Nutraceutical Exisulind Exisulind may decrease the antihypertensive activities of Bucindolol. Investigational Felbinac Felbinac may decrease the antihypertensive activities of Bucindolol. Experimental Felodipine The risk or severity of hypotension can be increased when Bucindolol is combined with Felodipine. Approved, Investigational Fenbufen Fenbufen may decrease the antihypertensive activities of Bucindolol. Approved Fendiline The risk or severity of hypotension can be increased when Bucindolol is combined with Fendiline. Withdrawn Fenoprofen Fenoprofen may decrease the antihypertensive activities of Bucindolol. Approved Fenoterol The risk or severity of adverse effects can be increased when Fenoterol is combined with Bucindolol. Approved, Investigational Fenozolone The risk or severity of adverse effects can be increased when Bucindolol is combined with Fenozolone. Experimental Fentanyl Fentanyl may increase the bradycardic activities of Bucindolol. Approved, Illicit, Investigational, Vet Approved Fenthion Fenthion may increase the bradycardic activities of Bucindolol. Vet Approved Fentiazac Fentiazac may decrease the antihypertensive activities of Bucindolol. Experimental Feprazone Feprazone may decrease the antihypertensive activities of Bucindolol. Experimental Ferulic acid Ferulic acid may decrease the antihypertensive activities of Bucindolol. Experimental Fingolimod Bucindolol may increase the bradycardic activities of Fingolimod. Approved, Investigational Fish oil The risk or severity of hypotension can be increased when Bucindolol is combined with Fish oil. Approved, Nutraceutical Floctafenine The risk or severity of adverse effects can be increased when Bucindolol is combined with Floctafenine. Approved, Withdrawn Flunarizine The risk or severity of hypotension can be increased when Bucindolol is combined with Flunarizine. Approved Flunixin Flunixin may decrease the antihypertensive activities of Bucindolol. Vet Approved Flunoxaprofen Flunoxaprofen may decrease the antihypertensive activities of Bucindolol. Experimental Fluoxetine The serum concentration of Bucindolol can be increased when it is combined with Fluoxetine. Approved, Vet Approved Fluphenazine Fluphenazine may increase the hypotensive activities of Bucindolol. Approved Flurbiprofen Flurbiprofen may decrease the antihypertensive activities of Bucindolol. Approved, Investigational Fluspirilene The risk or severity of hypotension can be increased when Bucindolol is combined with Fluspirilene. Approved, Investigational Formoterol Bucindolol may decrease the vasoconstricting activities of Formoterol. Approved, Investigational Gabapentin The risk or severity of hypotension can be increased when Bucindolol is combined with Gabapentin. Approved, Investigational Galantamine Galantamine may increase the bradycardic activities of Bucindolol. Approved Gallamine Triethiodide Gallamine Triethiodide may increase the bradycardic activities of Bucindolol. Approved Gallopamil The risk or severity of hypotension can be increased when Bucindolol is combined with Gallopamil. Investigational Gitoformate Bucindolol may increase the bradycardic activities of Gitoformate. Experimental Glibornuride Bucindolol may increase the hypoglycemic activities of Glibornuride. Investigational, Withdrawn Gliclazide Bucindolol may increase the hypoglycemic activities of Gliclazide. Approved Glimepiride Bucindolol may increase the hypoglycemic activities of Glimepiride. Approved Glipizide Bucindolol may increase the hypoglycemic activities of Glipizide. Approved, Investigational Gliquidone Bucindolol may increase the hypoglycemic activities of Gliquidone. Approved, Investigational Glisoxepide Bucindolol may increase the hypoglycemic activities of Glisoxepide. Investigational Glyburide Bucindolol may increase the hypoglycemic activities of Glyburide. Approved GTS-21 The risk or severity of adverse effects can be increased when Bucindolol is combined with GTS-21. Investigational Guacetisal Guacetisal may decrease the antihypertensive activities of Bucindolol. Experimental Guanabenz Guanabenz may increase the atrioventricular blocking (AV block) activities of Bucindolol. Approved, Investigational Guanfacine Guanfacine may increase the atrioventricular blocking (AV block) activities of Bucindolol. Approved, Investigational Hexobarbital The serum concentration of Bucindolol can be decreased when it is combined with Hexobarbital. Approved Hexoprenaline Bucindolol may decrease the vasoconstricting activities of Hexoprenaline. Approved, Withdrawn Higenamine Bucindolol may decrease the vasoconstricting activities of Higenamine. Investigational Huperzine A Huperzine A may increase the bradycardic activities of Bucindolol. Approved, Investigational Hydroxyamphetamine The risk or severity of adverse effects can be increased when Hydroxyamphetamine is combined with Bucindolol. Approved Hydroxychloroquine The metabolism of Bucindolol can be decreased when combined with Hydroxychloroquine. Approved Ibuprofen Ibuprofen may decrease the antihypertensive activities of Bucindolol. Approved Ibuproxam Ibuproxam may decrease the antihypertensive activities of Bucindolol. Withdrawn Icatibant Icatibant may decrease the antihypertensive activities of Bucindolol. Approved, Investigational Imidazole salicylate Imidazole salicylate may decrease the antihypertensive activities of Bucindolol. Experimental Indalpine The serum concentration of Bucindolol can be increased when it is combined with Indalpine. Investigational, Withdrawn Indenolol Indenolol may increase the orthostatic hypotensive activities of Bucindolol. Withdrawn Indobufen Indobufen may decrease the antihypertensive activities of Bucindolol. Investigational Indomethacin Indomethacin may decrease the antihypertensive activities of Bucindolol. Approved, Investigational Indoprofen Indoprofen may decrease the antihypertensive activities of Bucindolol. Withdrawn Indoramin Indoramin may increase the antihypertensive activities of Bucindolol. Withdrawn Insulin Human Bucindolol may increase the hypoglycemic activities of Insulin Human. Approved, Investigational Insulin Pork Bucindolol may increase the hypoglycemic activities of Insulin Pork. Approved Iobenguane The therapeutic efficacy of Iobenguane can be decreased when used in combination with Bucindolol. Approved, Investigational Ipidacrine Ipidacrine may increase the bradycardic activities of Bucindolol. Experimental Isoetarine Bucindolol may decrease the vasoconstricting activities of Isoetarine. Approved Isoflurophate Isoflurophate may increase the bradycardic activities of Bucindolol. Approved, Investigational, Withdrawn Isoprenaline The risk or severity of adverse effects can be increased when Isoprenaline is combined with Bucindolol. Approved, Investigational Isoxicam Isoxicam may decrease the antihypertensive activities of Bucindolol. Withdrawn Isoxsuprine The risk or severity of adverse effects can be increased when Isoxsuprine is combined with Bucindolol. Approved, Withdrawn Isradipine The risk or severity of hypotension can be increased when Bucindolol is combined with Isradipine. Approved, Investigational Kebuzone Kebuzone may decrease the antihypertensive activities of Bucindolol. Experimental Ketoprofen Ketoprofen may decrease the antihypertensive activities of Bucindolol. Approved, Vet Approved Ketorolac Ketorolac may decrease the antihypertensive activities of Bucindolol. Approved Labetalol Labetalol may increase the antihypertensive activities of Bucindolol. Approved Lacidipine The risk or severity of hypotension can be increased when Bucindolol is combined with Lacidipine. Approved, Investigational Lamotrigine The risk or severity of hypotension can be increased when Bucindolol is combined with Lamotrigine. Approved, Investigational Lanatoside C Bucindolol may increase the bradycardic activities of Lanatoside C. Experimental Landiolol Landiolol may increase the orthostatic hypotensive activities of Bucindolol. Investigational Leflunomide Leflunomide may decrease the antihypertensive activities of Bucindolol. Approved, Investigational Lercanidipine The risk or severity of hypotension can be increased when Bucindolol is combined with Lercanidipine. Approved, Investigational Levetiracetam The risk or severity of hypotension can be increased when Bucindolol is combined with Levetiracetam. Approved, Investigational Levomilnacipran The serum concentration of Bucindolol can be increased when it is combined with Levomilnacipran. Approved, Investigational Levonordefrin Levonordefrin may increase the atrioventricular blocking (AV block) activities of Bucindolol. Approved Lidocaine The serum concentration of Lidocaine can be increased when it is combined with Bucindolol. Approved, Vet Approved Lidoflazine The risk or severity of hypotension can be increased when Bucindolol is combined with Lidoflazine. Experimental Linezolid Linezolid may increase the hypertensive activities of Bucindolol. Approved, Investigational Lisofylline Lisofylline may decrease the antihypertensive activities of Bucindolol. Investigational Lobeline The risk or severity of adverse effects can be increased when Bucindolol is combined with Lobeline. Investigational Lofexidine Lofexidine may increase the atrioventricular blocking (AV block) activities of Bucindolol. Approved, Investigational Lonazolac Lonazolac may decrease the antihypertensive activities of Bucindolol. Experimental Loperamide The risk or severity of hypotension can be increased when Bucindolol is combined with Loperamide. Approved Lornoxicam Lornoxicam may decrease the antihypertensive activities of Bucindolol. Approved, Investigational Loxoprofen Loxoprofen may decrease the antihypertensive activities of Bucindolol. Approved, Investigational Lumiracoxib Lumiracoxib may decrease the antihypertensive activities of Bucindolol. Approved, Investigational Magnesium salicylate Magnesium salicylate may decrease the antihypertensive activities of Bucindolol. Approved Magnesium sulfate The risk or severity of hypotension can be increased when Bucindolol is combined with Magnesium sulfate. Approved, Investigational, Vet Approved Malathion Malathion may increase the bradycardic activities of Bucindolol. Approved, Investigational Manidipine The risk or severity of hypotension can be increased when Bucindolol is combined with Manidipine. Approved, Investigational Masoprocol Masoprocol may decrease the antihypertensive activities of Bucindolol. Approved, Investigational Meclofenamic acid Meclofenamic acid may decrease the antihypertensive activities of Bucindolol. Approved, Vet Approved Medetomidine Bucindolol may decrease the vasoconstricting activities of Medetomidine. Vet Approved Mefenamic acid Mefenamic acid may decrease the antihypertensive activities of Bucindolol. Approved Mefenorex The risk or severity of adverse effects can be increased when Bucindolol is combined with Mefenorex. Experimental Mefloquine Mefloquine may increase the bradycardic activities of Bucindolol. Approved, Investigational Meloxicam Meloxicam may decrease the antihypertensive activities of Bucindolol. Approved, Vet Approved Memantine Memantine may increase the bradycardic activities of Bucindolol. Approved, Investigational Menthol The risk or severity of hypotension can be increased when Bucindolol is combined with Menthol. Approved Mephentermine Bucindolol may decrease the vasoconstricting activities of Mephentermine. Approved Mepindolol Mepindolol may increase the orthostatic hypotensive activities of Bucindolol. Experimental Mepivacaine The serum concentration of Mepivacaine can be increased when it is combined with Bucindolol. Approved, Vet Approved Mesalazine Mesalazine may decrease the antihypertensive activities of Bucindolol. Approved Mesoridazine Mesoridazine may increase the hypotensive activities of Bucindolol. Approved, Investigational Metahexamide Bucindolol may increase the hypoglycemic activities of Metahexamide. Experimental Metamizole Metamizole may decrease the antihypertensive activities of Bucindolol. Approved, Investigational, Withdrawn Metaraminol Bucindolol may decrease the vasoconstricting activities of Metaraminol. Approved, Investigational Methacholine Bucindolol may increase the bronchoconstrictory activities of Methacholine. Approved, Investigational Methamphetamine Methamphetamine may increase the atrioventricular blocking (AV block) activities of Bucindolol. Approved, Illicit Methanesulfonyl Fluoride Methanesulfonyl Fluoride may increase the bradycardic activities of Bucindolol. Investigational Methohexital The serum concentration of Bucindolol can be decreased when it is combined with Methohexital. Approved Methotrimeprazine Methotrimeprazine may increase the hypotensive activities of Bucindolol. Approved, Investigational Methoxamine Bucindolol may decrease the vasoconstricting activities of Methoxamine. Approved, Investigational Methoxyphenamine Bucindolol may decrease the vasoconstricting activities of Methoxyphenamine. Experimental Methsuximide The risk or severity of hypotension can be increased when Bucindolol is combined with Methsuximide. Approved Methyldopa Bucindolol may decrease the vasoconstricting activities of Methyldopa. Approved Methylene blue Methylene blue may increase the hypotensive activities of Bucindolol. Approved, Investigational Methylergometrine Bucindolol may increase the vasoconstricting activities of Methylergometrine. Approved Methylphenobarbital The serum concentration of Bucindolol can be decreased when it is combined with Methylphenobarbital. Approved Metildigoxin Bucindolol may increase the bradycardic activities of Metildigoxin. Experimental Metoclopramide Metoclopramide may increase the bradycardic activities of Bucindolol. Approved, Investigational Metoprolol Metoprolol may increase the orthostatic hypotensive activities of Bucindolol. Approved, Investigational Mibefradil The risk or severity of hypotension can be increased when Bucindolol is combined with Mibefradil. Investigational, Withdrawn Midodrine Bucindolol may increase the bradycardic activities of Midodrine. Approved Milnacipran The serum concentration of Bucindolol can be increased when it is combined with Milnacipran. Approved, Investigational Minaprine Minaprine may increase the bradycardic activities of Bucindolol. Approved Mirabegron Bucindolol may decrease the vasoconstricting activities of Mirabegron. Approved Mirodenafil Mirodenafil may increase the hypotensive activities of Bucindolol. Investigational Mizoribine Mizoribine may decrease the antihypertensive activities of Bucindolol. Investigational Mofebutazone Mofebutazone may decrease the antihypertensive activities of Bucindolol. Experimental Moricizine Moricizine may increase the hypotensive activities of Bucindolol. Approved, Investigational, Withdrawn Moxonidine Moxonidine may increase the atrioventricular blocking (AV block) activities of Bucindolol. Approved, Investigational Mycophenolate mofetil Mycophenolate mofetil may decrease the antihypertensive activities of Bucindolol. Approved, Investigational Mycophenolic acid Mycophenolic acid may decrease the antihypertensive activities of Bucindolol. Approved Nabilone Nabilone may increase the tachycardic activities of Bucindolol. Approved, Investigational Nabumetone Nabumetone may decrease the antihypertensive activities of Bucindolol. Approved Nadolol Nadolol may increase the orthostatic hypotensive activities of Bucindolol. Approved Nafamostat Nafamostat may decrease the antihypertensive activities of Bucindolol. Approved, Investigational Naftifine Naftifine may decrease the antihypertensive activities of Bucindolol. Approved Naftopidil The risk or severity of hypotension can be increased when Bucindolol is combined with Naftopidil. Investigational Naphazoline Naphazoline may increase the atrioventricular blocking (AV block) activities of Bucindolol. Approved Naproxen Naproxen may decrease the antihypertensive activities of Bucindolol. Approved, Vet Approved Nebivolol Nebivolol may increase the orthostatic hypotensive activities of Bucindolol. Approved, Investigational Nefazodone The serum concentration of Bucindolol can be increased when it is combined with Nefazodone. Approved, Withdrawn Neostigmine Neostigmine may increase the bradycardic activities of Bucindolol. Approved, Vet Approved Nepafenac Nepafenac may decrease the antihypertensive activities of Bucindolol. Approved, Investigational Nicardipine The risk or severity of hypotension can be increased when Bucindolol is combined with Nicardipine. Approved, Investigational Nicotine The risk or severity of adverse effects can be increased when Bucindolol is combined with Nicotine. Approved Nifedipine The risk or severity of congestive heart failure and hypotension can be increased when Nifedipine is combined with Bucindolol. Approved Nifenazone Nifenazone may decrease the antihypertensive activities of Bucindolol. Experimental Niflumic Acid Niflumic Acid may decrease the antihypertensive activities of Bucindolol. Approved Niguldipine The risk or severity of hypotension can be increased when Bucindolol is combined with Niguldipine. Experimental Niludipine The risk or severity of hypotension can be increased when Bucindolol is combined with Niludipine. Experimental Nilvadipine The risk or severity of hypotension can be increased when Bucindolol is combined with Nilvadipine. Approved, Investigational Nimesulide The risk or severity of hypotension can be increased when Bucindolol is combined with Nimesulide. Approved, Investigational, Withdrawn Nimodipine The risk or severity of hypotension can be increased when Bucindolol is combined with Nimodipine. Approved, Investigational Nisoldipine The risk or severity of hypotension can be increased when Bucindolol is combined with Nisoldipine. Approved Nitrendipine The risk or severity of hypotension can be increased when Bucindolol is combined with Nitrendipine. Approved, Investigational Nitroaspirin Nitroaspirin may decrease the antihypertensive activities of Bucindolol. Investigational Norepinephrine Norepinephrine may increase the atrioventricular blocking (AV block) activities of Bucindolol. Approved Norfenefrine Bucindolol may decrease the vasoconstricting activities of Norfenefrine. Experimental Nylidrin The risk or severity of adverse effects can be increased when Nylidrin is combined with Bucindolol. Approved Octopamine Bucindolol may decrease the vasoconstricting activities of Octopamine. Experimental Oleandrin Bucindolol may increase the bradycardic activities of Oleandrin. Experimental, Investigational Olodaterol Bucindolol may decrease the vasoconstricting activities of Olodaterol. Approved Olopatadine Olopatadine may decrease the antihypertensive activities of Bucindolol. Approved Olsalazine Olsalazine may decrease the antihypertensive activities of Bucindolol. Approved Orciprenaline The risk or severity of adverse effects can be increased when Orciprenaline is combined with Bucindolol. Approved Orgotein Orgotein may decrease the antihypertensive activities of Bucindolol. Vet Approved Otilonium The risk or severity of hypotension can be increased when Bucindolol is combined with Otilonium. Experimental, Investigational Ouabain Bucindolol may increase the bradycardic activities of Ouabain. Approved Oxaprozin Oxaprozin may decrease the antihypertensive activities of Bucindolol. Approved Oxprenolol Oxprenolol may increase the orthostatic hypotensive activities of Bucindolol. Approved Oxyfedrine Bucindolol may decrease the vasoconstricting activities of Oxyfedrine. Experimental Oxymetazoline Oxymetazoline may increase the atrioventricular blocking (AV block) activities of Bucindolol. Approved, Investigational Oxyphenbutazone Oxyphenbutazone may decrease the antihypertensive activities of Bucindolol. Approved, Withdrawn Paliperidone Paliperidone may increase the atrioventricular blocking (AV block) activities of Bucindolol. Approved Paraoxon Paraoxon may increase the bradycardic activities of Bucindolol. Experimental Parecoxib Parecoxib may decrease the antihypertensive activities of Bucindolol. Approved Paroxetine The serum concentration of Bucindolol can be increased when it is combined with Paroxetine. Approved, Investigational Parthenolide Parthenolide may decrease the antihypertensive activities of Bucindolol. Approved, Investigational Penbutolol Penbutolol may increase the orthostatic hypotensive activities of Bucindolol. Approved, Investigational Pentobarbital The serum concentration of Bucindolol can be decreased when it is combined with Pentobarbital. Approved, Investigational, Vet Approved Perazine Perazine may increase the hypotensive activities of Bucindolol. Approved, Investigational Pergolide Pergolide may increase the atrioventricular blocking (AV block) activities of Bucindolol. Approved, Investigational, Vet Approved, Withdrawn Perphenazine Perphenazine may increase the hypotensive activities of Bucindolol. Approved Peruvoside Bucindolol may increase the bradycardic activities of Peruvoside. Experimental Phenmetrazine The risk or severity of adverse effects can be increased when Phenmetrazine is combined with Bucindolol. Approved, Illicit Phenobarbital The serum concentration of Bucindolol can be decreased when it is combined with Phenobarbital. Approved, Investigational Phentermine The risk or severity of adverse effects can be increased when Phentermine is combined with Bucindolol. Approved, Illicit Phenylbutazone Phenylbutazone may decrease the antihypertensive activities of Bucindolol. Approved, Vet Approved Phenylephrine Bucindolol may decrease the vasoconstricting activities of Phenylephrine. Approved Phenylpropanolamine The risk or severity of adverse effects can be increased when Phenylpropanolamine is combined with Bucindolol. Approved, Vet Approved, Withdrawn Physostigmine Physostigmine may increase the bradycardic activities of Bucindolol. Approved, Investigational Pilocarpine The risk or severity of adverse effects can be increased when Bucindolol is combined with Pilocarpine. Approved, Investigational Pimecrolimus Pimecrolimus may decrease the antihypertensive activities of Bucindolol. Approved, Investigational Pinaverium The risk or severity of hypotension can be increased when Bucindolol is combined with Pinaverium. Approved Pindolol Pindolol may increase the orthostatic hypotensive activities of Bucindolol. Approved, Investigational Pirbuterol Bucindolol may decrease the vasoconstricting activities of Pirbuterol. Approved Pirfenidone Pirfenidone may decrease the antihypertensive activities of Bucindolol. Approved, Investigational Piroxicam Piroxicam may decrease the antihypertensive activities of Bucindolol. Approved, Investigational Pirprofen Pirprofen may decrease the antihypertensive activities of Bucindolol. Experimental Platelet Activating Factor Platelet Activating Factor may increase the orthostatic hypotensive activities of Bucindolol. Experimental Practolol Practolol may increase the orthostatic hypotensive activities of Bucindolol. Approved Pranoprofen Pranoprofen may decrease the antihypertensive activities of Bucindolol. Experimental, Investigational Prazosin Prazosin may increase the antihypertensive activities of Bucindolol. Approved Prenalterol The risk or severity of adverse effects can be increased when Bucindolol is combined with Prenalterol. Experimental Prenylamine The risk or severity of hypotension can be increased when Bucindolol is combined with Prenylamine. Withdrawn Primaquine The metabolism of Bucindolol can be decreased when combined with Primaquine. Approved Primidone The serum concentration of Bucindolol can be decreased when it is combined with Primidone. Approved, Vet Approved Procaterol The risk or severity of adverse effects can be increased when Procaterol is combined with Bucindolol. Approved, Investigational Prochlorperazine Prochlorperazine may increase the hypotensive activities of Bucindolol. Approved, Vet Approved Proglumetacin Proglumetacin may decrease the antihypertensive activities of Bucindolol. Experimental Promazine Promazine may increase the hypotensive activities of Bucindolol. Approved, Vet Approved Promethazine Promethazine may increase the hypotensive activities of Bucindolol. Approved, Investigational Propacetamol Propacetamol may decrease the antihypertensive activities of Bucindolol. Approved, Investigational Propafenone The serum concentration of Bucindolol can be increased when it is combined with Propafenone. Approved Propericiazine Propericiazine may increase the hypotensive activities of Bucindolol. Approved, Investigational Propiopromazine Propiopromazine may increase the hypotensive activities of Bucindolol. Vet Approved Propranolol Propranolol may increase the orthostatic hypotensive activities of Bucindolol. Approved, Investigational Propyphenazone Propyphenazone may decrease the antihypertensive activities of Bucindolol. Experimental Proquazone Proquazone may decrease the antihypertensive activities of Bucindolol. Experimental Proscillaridin Bucindolol may increase the bradycardic activities of Proscillaridin. Experimental Pseudoephedrine Pseudoephedrine may increase the atrioventricular blocking (AV block) activities of Bucindolol. Approved PTC299 PTC299 may decrease the antihypertensive activities of Bucindolol. Investigational Pyridostigmine Pyridostigmine may increase the bradycardic activities of Bucindolol. Approved, Investigational Racepinephrine Racepinephrine may increase the atrioventricular blocking (AV block) activities of Bucindolol. Approved Ractopamine Bucindolol may decrease the vasoconstricting activities of Ractopamine. Vet Approved Regorafenib Regorafenib may increase the bradycardic activities of Bucindolol. Approved Remifentanil Remifentanil may increase the bradycardic activities of Bucindolol. Approved Reproterol Bucindolol may decrease the vasoconstricting activities of Reproterol. Investigational Reserpine Reserpine may increase the hypotensive activities of Bucindolol. Approved, Investigational Resveratrol Resveratrol may decrease the antihypertensive activities of Bucindolol. Approved, Experimental, Investigational Rifampicin The serum concentration of Bucindolol can be decreased when it is combined with Rifampicin. Approved Rifapentine The serum concentration of Bucindolol can be decreased when it is combined with Rifapentine. Approved, Investigational Rifaximin The serum concentration of Bucindolol can be decreased when it is combined with Rifaximin. Approved, Investigational Rilmenidine Bucindolol may decrease the vasoconstricting activities of Rilmenidine. Approved, Investigational Rimiterol Bucindolol may decrease the vasoconstricting activities of Rimiterol. Experimental Risperidone Risperidone may increase the atrioventricular blocking (AV block) activities of Bucindolol. Approved, Investigational Ritobegron Bucindolol may decrease the vasoconstricting activities of Ritobegron. Investigational Ritodrine The risk or severity of adverse effects can be increased when Ritodrine is combined with Bucindolol. Approved, Investigational Rivastigmine Bucindolol may increase the bradycardic activities of Rivastigmine. Approved, Investigational Rofecoxib Rofecoxib may decrease the antihypertensive activities of Bucindolol. Approved, Investigational, Withdrawn Romifidine Bucindolol may decrease the vasoconstricting activities of Romifidine. Vet Approved Ropinirole Ropinirole may increase the atrioventricular blocking (AV block) activities of Bucindolol. Approved, Investigational Salbutamol Bucindolol may decrease the vasoconstricting activities of Salbutamol. Approved, Vet Approved Salicylamide Salicylamide may decrease the antihypertensive activities of Bucindolol. Approved Salicylic acid Salicylic acid may decrease the antihypertensive activities of Bucindolol. Approved, Investigational, Vet Approved Salmeterol Bucindolol may decrease the vasoconstricting activities of Salmeterol. Approved Salsalate Salsalate may decrease the antihypertensive activities of Bucindolol. Approved Secobarbital The serum concentration of Bucindolol can be decreased when it is combined with Secobarbital. Approved, Vet Approved Seletracetam The risk or severity of hypotension can be increased when Bucindolol is combined with Seletracetam. Investigational Semapimod Semapimod may decrease the antihypertensive activities of Bucindolol. Investigational Seratrodast Seratrodast may decrease the antihypertensive activities of Bucindolol. Approved Serrapeptase Serrapeptase may decrease the antihypertensive activities of Bucindolol. Investigational Sertraline The serum concentration of Bucindolol can be increased when it is combined with Sertraline. Approved Sildenafil Sildenafil may increase the hypotensive activities of Bucindolol. Approved, Investigational Silodosin Silodosin may increase the antihypertensive activities of Bucindolol. Approved Solabegron Bucindolol may decrease the vasoconstricting activities of Solabegron. Investigational Sotalol Sotalol may increase the orthostatic hypotensive activities of Bucindolol. Approved SRT501 SRT501 may decrease the antihypertensive activities of Bucindolol. Investigational Sufentanil Sufentanil may increase the bradycardic activities of Bucindolol. Approved, Investigational Sulfasalazine Sulfasalazine may decrease the antihypertensive activities of Bucindolol. Approved Sulindac Sulindac may decrease the antihypertensive activities of Bucindolol. Approved, Investigational Suprofen Suprofen may decrease the antihypertensive activities of Bucindolol. Approved, Withdrawn Suxibuzone Suxibuzone may decrease the antihypertensive activities of Bucindolol. Experimental Synephrine The risk or severity of adverse effects can be increased when Synephrine is combined with Bucindolol. Experimental Tacrine Tacrine may increase the bradycardic activities of Bucindolol. Investigational, Withdrawn Tadalafil Tadalafil may increase the hypotensive activities of Bucindolol. Approved, Investigational Tafenoquine The metabolism of Bucindolol can be decreased when combined with Tafenoquine. Investigational Talinolol Talinolol may increase the orthostatic hypotensive activities of Bucindolol. Investigational Tamsulosin Tamsulosin may increase the antihypertensive activities of Bucindolol. Approved, Investigational Tarenflurbil Tarenflurbil may decrease the antihypertensive activities of Bucindolol. Investigational Tedizolid Phosphate Tedizolid Phosphate may increase the hypertensive activities of Bucindolol. Approved Tenidap Tenidap may decrease the antihypertensive activities of Bucindolol. Experimental Tenoxicam Tenoxicam may decrease the antihypertensive activities of Bucindolol. Approved Tepoxalin Tepoxalin may decrease the antihypertensive activities of Bucindolol. Vet Approved Terazosin Terazosin may increase the antihypertensive activities of Bucindolol. Approved Terbutaline The risk or severity of adverse effects can be increased when Terbutaline is combined with Bucindolol. Approved Teriflunomide Teriflunomide may decrease the antihypertensive activities of Bucindolol. Approved Terodiline The risk or severity of hypotension can be increased when Bucindolol is combined with Terodiline. Experimental Tertatolol Tertatolol may increase the orthostatic hypotensive activities of Bucindolol. Experimental Tetrahydropalmatine The risk or severity of hypotension can be increased when Bucindolol is combined with Tetrahydropalmatine. Investigational Tetryzoline The risk or severity of adverse effects can be increased when Tetryzoline is combined with Bucindolol. Approved Thiamylal The serum concentration of Bucindolol can be decreased when it is combined with Thiamylal. Approved, Vet Approved Thiazinam Thiazinam may increase the hypotensive activities of Bucindolol. Experimental Thiethylperazine Thiethylperazine may increase the hypotensive activities of Bucindolol. Withdrawn Thiopental The serum concentration of Bucindolol can be decreased when it is combined with Thiopental. Approved, Vet Approved Thioproperazine Thioproperazine may increase the hypotensive activities of Bucindolol. Approved Thioridazine Thioridazine may increase the hypotensive activities of Bucindolol. Approved, Withdrawn Tiaprofenic acid Tiaprofenic acid may decrease the antihypertensive activities of Bucindolol. Approved Timolol Timolol may increase the orthostatic hypotensive activities of Bucindolol. Approved Tinoridine Tinoridine may decrease the antihypertensive activities of Bucindolol. Investigational Tizanidine Tizanidine may increase the atrioventricular blocking (AV block) activities of Bucindolol. Approved, Investigational Tolazamide Bucindolol may increase the hypoglycemic activities of Tolazamide. Approved, Investigational Tolbutamide Bucindolol may increase the hypoglycemic activities of Tolbutamide. Approved, Investigational Tolfenamic Acid The risk or severity of hypotension can be increased when Bucindolol is combined with Tolfenamic Acid. Approved, Investigational Tolmetin Tolmetin may decrease the antihypertensive activities of Bucindolol. Approved Tramazoline The risk or severity of adverse effects can be increased when Bucindolol is combined with Tramazoline. Investigational Tranilast The risk or severity of hypotension can be increased when Bucindolol is combined with Tranilast. Approved, Investigational Tretoquinol The risk or severity of adverse effects can be increased when Bucindolol is combined with Tretoquinol. Experimental Tribenoside Tribenoside may decrease the antihypertensive activities of Bucindolol. Experimental Trichlorfon Trichlorfon may increase the bradycardic activities of Bucindolol. Vet Approved Trifluoperazine Trifluoperazine may increase the hypotensive activities of Bucindolol. Approved, Investigational Triflupromazine Triflupromazine may increase the hypotensive activities of Bucindolol. Approved, Vet Approved Trimazosin Trimazosin may increase the antihypertensive activities of Bucindolol. Experimental Trimebutine The risk or severity of hypotension can be increased when Bucindolol is combined with Trimebutine. Approved Trimethadione The risk or severity of hypotension can be increased when Bucindolol is combined with Trimethadione. Approved Triptolide Triptolide may decrease the antihypertensive activities of Bucindolol. Investigational Tubocurarine Tubocurarine may increase the bradycardic activities of Bucindolol. Approved Tulobuterol Bucindolol may decrease the vasoconstricting activities of Tulobuterol. Investigational Tyramine The risk or severity of adverse effects can be increased when Tyramine is combined with Bucindolol. Investigational, Nutraceutical Tyrothricin Tyrothricin may increase the bradycardic activities of Bucindolol. Approved Udenafil Udenafil may increase the hypotensive activities of Bucindolol. Approved, Investigational Urapidil Urapidil may increase the antihypertensive activities of Bucindolol. Investigational Valdecoxib Valdecoxib may decrease the antihypertensive activities of Bucindolol. Approved, Investigational, Withdrawn Vardenafil Vardenafil may increase the hypotensive activities of Bucindolol. Approved Varenicline The risk or severity of adverse effects can be increased when Bucindolol is combined with Varenicline. Approved, Investigational Venlafaxine The serum concentration of Bucindolol can be increased when it is combined with Venlafaxine. Approved Verapamil Verapamil may increase the hypotensive activities of Bucindolol. Approved Vinpocetine The risk or severity of hypotension can be increased when Bucindolol is combined with Vinpocetine. Investigational WIN 55212-2 The risk or severity of hypotension can be increased when Bucindolol is combined with WIN 55212-2. Experimental Xamoterol Bucindolol may decrease the vasoconstricting activities of Xamoterol. Experimental Xylazine Xylazine may increase the atrioventricular blocking (AV block) activities of Bucindolol. Vet Approved Xylometazoline Xylometazoline may increase the atrioventricular blocking (AV block) activities of Bucindolol. Approved, Investigational Zaltoprofen Zaltoprofen may decrease the antihypertensive activities of Bucindolol. Approved, Investigational Ziconotide The risk or severity of hypotension can be increased when Bucindolol is combined with Ziconotide. Approved Zileuton Zileuton may decrease the antihypertensive activities of Bucindolol. Approved, Investigational, Withdrawn Zimelidine The serum concentration of Bucindolol can be increased when it is combined with Zimelidine. Withdrawn Zomepirac Zomepirac may decrease the antihypertensive activities of Bucindolol. Withdrawn Zonisamide The risk or severity of hypotension can be increased when Bucindolol is combined with Zonisamide. Approved, Investigational - Food Interactions
- Not Available
References
- General References
- Not Available
- External Links
- PubChem Compound
- 51045
- PubChem Substance
- 347828941
- ChemSpider
- 46266
- BindingDB
- 50169808
- ChEMBL
- CHEMBL321582
- PharmGKB
- PA165945764
- Wikipedia
- Bucindolol
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 2 Completed Treatment Current or Recent History of Atrial Fibrillation 1 Not Available Unknown Status Not Available Heart Failure, Unspecified 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.00744 mg/mL ALOGPS logP 3.4 ALOGPS logP 3.49 ChemAxon logS -4.7 ALOGPS pKa (Strongest Acidic) 14.09 ChemAxon pKa (Strongest Basic) 9.69 ChemAxon Physiological Charge 1 ChemAxon Hydrogen Acceptor Count 4 ChemAxon Hydrogen Donor Count 3 ChemAxon Polar Surface Area 81.07 Å2 ChemAxon Rotatable Bond Count 8 ChemAxon Refractivity 106.44 m3·mol-1 ChemAxon Polarizability 39.98 Å3 ChemAxon Number of Rings 3 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter Yes ChemAxon Veber's Rule No ChemAxon MDDR-like Rule Yes ChemAxon - Predicted ADMET features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Taxonomy
- Description
- This compound belongs to the class of organic compounds known as 3-alkylindoles. These are compounds containing an indole moiety that carries an alkyl chain at the 3-position.
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Indoles and derivatives
- Sub Class
- Indoles
- Direct Parent
- 3-alkylindoles
- Alternative Parents
- Phenoxy compounds / Phenol ethers / Benzonitriles / Aralkylamines / Alkyl aryl ethers / Substituted pyrroles / Heteroaromatic compounds / Secondary alcohols / 1,2-aminoalcohols / Nitriles show 4 more
- Substituents
- 3-alkylindole / Phenoxy compound / Benzonitrile / Phenol ether / Alkyl aryl ether / Aralkylamine / Monocyclic benzene moiety / Benzenoid / Substituted pyrrole / Heteroaromatic compound show 18 more
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- Not Available
Drug created on October 20, 2016 18:01 / Updated on May 02, 2018 00:24